Cumberland Pharmaceuticals Inc.
CPIX
$4.35
-$1.01-18.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.71M | 9.11M | 9.09M | 9.85M | 8.50M |
| Total Other Revenue | -- | 1.33M | -- | -- | -- |
| Total Revenue | 11.71M | 10.44M | 9.09M | 9.85M | 8.50M |
| Cost of Revenue | 1.43M | 1.98M | 1.32M | 1.71M | 1.58M |
| Gross Profit | 10.29M | 8.46M | 7.76M | 8.14M | 6.92M |
| SG&A Expenses | 6.70M | 7.55M | 7.07M | 7.01M | 6.52M |
| Depreciation & Amortization | 1.01M | 1.46M | 1.08M | 1.10M | 1.11M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.42M | 12.28M | 10.78M | 10.88M | 10.37M |
| Operating Income | 1.29M | -1.84M | -1.69M | -1.03M | -1.87M |
| Income Before Tax | 1.25M | -1.96M | -1.53M | -1.09M | -1.89M |
| Income Tax Expenses | 5.70K | -57.00K | 11.40K | 11.40K | 11.40K |
| Earnings from Continuing Operations | 1.25M | -1.90M | -1.54M | -1.10M | -1.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.90K | -2.20K | -7.10K | 17.00K | -43.80K |
| Net Income | 1.26M | -1.90M | -1.54M | -1.09M | -1.95M |
| EBIT | 1.29M | -1.84M | -1.69M | -1.03M | -1.87M |
| EBITDA | 2.32M | -345.60K | -578.40K | 112.80K | -718.60K |
| EPS Basic | 0.08 | -0.14 | -0.11 | -0.08 | -0.14 |
| Normalized Basic EPS | 0.05 | -0.09 | -0.08 | -0.05 | -0.09 |
| EPS Diluted | 0.08 | -0.14 | -0.11 | -0.08 | -0.14 |
| Normalized Diluted EPS | 0.05 | -0.09 | -0.08 | -0.05 | -0.09 |
| Average Basic Shares Outstanding | 14.94M | 13.97M | 14.05M | 14.12M | 14.10M |
| Average Diluted Shares Outstanding | 15.26M | 13.97M | 14.05M | 14.12M | 14.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |